The clinical performance is complex and often involves multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment programs. Treatment and management of HL over the age of 50 require individualized development of treatment programs, typically including drug therapy, rehabilitation interventions, and regular follow-up multi-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL patients over 50 years of age. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.